Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Briefly, in accordance with one or more embodiments, an analytic system controls operation of a machine. The analytic system includes a sensor device to monitor power utilized by the machine, and to collect load data for the machine during startup. The analytic system further includes an analytic engine to determine a start time for the machine based at least in part on the load data for the machine received from the sensor device, and to communicate the determined start time to the machine. Start times for multiple machines may be selected wherein a maximum allowable current is not exceeded during the startup of the machines based at least in part on startup signatures for the machines generated from the load data.

Abstract: Methods and genetically engineered hosts for the production of 3-carbon, 4-carbon and 5-carbon products, polymers and copolymers in methylotrophic bacteria are described herein.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: An electronic apparatus includes a first main body and a second main body. The first main body includes a first surface and a second surface opposite the first surface. The second main body includes a base, a first fixing block and a second fixing block each protrusively arranged on the base and opposite to each other. When the first main body is inserted into the second main body with the first surface facing the second main body, a first end of the first main body is clamped between the first fixing block and the base and is supported by the second fixing block. When the first main body is inserted into the second main body with the second surface facing the second main body, the first end is clamped between the second fixing block and the base and is supported by the first fixing block.

Abstract: An electronic apparatus includes a first main body and a second main body. The first main body includes a first surface and a second surface opposite the first surface. The second main body includes a base, a first fixing block and a second fixing block each protrusively arranged on the base and opposite to each other. When the first main body is inserted into the second main body with the first surface facing the second main body, a first end of the first main body is clamped between the first fixing block and the base and is supported by the second fixing block. When the first main body is inserted into the second main body with the second surface facing the second main body, the first end is clamped between the second fixing block and the base and is supported by the first fixing block.

Abstract: A universal power adapter to allow only the plug desired to stick out smoothly in a simple construction and allowing convenient operation is comprised of a lid, a base, a rotary switch, and multiple plugs; multiple channels being disposed on the external wall of the base, a standardized plug being inserted to each channel; a rotary switch containing a bar sliding block and a braking pushbutton; the bar sliding block containing a bar slide and a gap; the pushbutton being inserted into the gap; a protruding block and a slot below being disposed to the top of the plug; the slot receiving the insertion end of the braking pushbutton; and the pushbutton sliding in the channel on the external wall of the base; and the protruding block of each plug being inserted into the bar slide of the bar sliding block to slide against the protruding block.

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.

Abstract: A magnetic flowmeter for measuring flow of a conductive fluid includes a flow tube assembly adapted to receive a fluid flow and a coil configured to apply a magnetic field in the fluid flow through the flow tube. An EMF sensor coupled to the flow tube provides an EMF output related to an EMF generated in the fluid flow due to the applied magnetic field, velocity of the fluid and noise. A signal processor includes a wavelet transformer that performs a wavelet transformation on the EMF output and provides a decomposition signal related to velocity of the fluid.

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).